Pharmaceutical Company
Appears in 1 story
Drug sponsor and U.S. commercial lead for Bizengri
Patients with advanced bile duct cancer driven by a rare genetic fusion called NRG1 had nothing approved for them after chemotherapy failed. On May 8, the U.S. Food and Drug Administration (FDA) approved Bizengri (zenocutuzumab-zbco), made by Partner Therapeutics, as the first drug aimed at this small group. It works by blocking the abnormal protein the NRG1 fusion produces, which fuels tumor growth.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
